Pharming Group (NASDAQ:PHAR - Get Free Report) traded up 5.4% on Tuesday . The stock traded as high as $9.25 and last traded at $9.59. 2,252 shares traded hands during trading, a decline of 58% from the average session volume of 5,358 shares. The stock had previously closed at $9.10.
Wall Street Analysts Forecast Growth
PHAR has been the subject of several research reports. Jefferies Financial Group assumed coverage on Pharming Group in a research note on Monday, December 9th. They issued a "buy" rating and a $14.00 target price for the company. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a research note on Tuesday, December 17th. Finally, Oppenheimer decreased their price objective on Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, October 28th.
View Our Latest Research Report on PHAR
Pharming Group Trading Down 1.3 %
The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $602.33 million, a P/E ratio of -34.15 and a beta of -0.08. The firm's 50-day moving average price is $9.04 and its 200 day moving average price is $8.43.
Institutional Trading of Pharming Group
An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 41,110 shares of the company's stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.06% of Pharming Group worth $339,000 at the end of the most recent quarter. 0.03% of the stock is owned by institutional investors and hedge funds.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
